Buchang Pharma subsidiary withdraws diabetes drug application, boosts device capital

Shandong Buchang Pharmaceuticals Co., Ltd. announced that its wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., has withdrawn its drug marketing authorization application for Empagliflozin Tablets, a type 2 diabetes treatment. The decision, made to refine application materials, is not a termination of the project, with plans to resubmit after further research. The company's R&D investment in the Empagliflozin Tablets project was approximately CNY 1,500.68 million. The withdrawal is not expected to significantly impact current period performance.

Concurrently, Shandong Buchang Pharmaceuticals increased the registered capital of its holding subsidiary, Jinan Buchang Shengyuan Medical Device Co., Ltd., from CNY 1,000万元 to CNY 1,300万元. This capital injection of CNY 300万元 was approved on October 29, 2025, and finalized on December 12, 2025. Following the capital increase, Buchang Pharmaceuticals maintains a 90% ownership stake in Jinan Buchang Shengyuan Medical Device Co., Ltd.